Jaguar Health Files 8-K: Material Agreement & Equity Sales
Ticker: JAGX · Form: 8-K · Filed: 2025-10-01T00:00:00.000Z
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Jaguar Health signed a big deal and sold stock, filing it all on Oct 1st.
AI Summary
On September 28, 2025, Jaguar Health, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on October 1, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements and unregistered equity sales can introduce financial and operational risks, requiring careful scrutiny.
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- September 28, 2025 (date) — Date of earliest event reported
- October 1, 2025 (date) — Filing date
- 200 Pine Street Suite 400 San Francisco, California 94104 (address) — Principal Executive Offices
FAQ
What type of material definitive agreement did Jaguar Health, Inc. enter into?
The filing states that Jaguar Health, Inc. entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 28, 2025.
What is the principal executive office address for Jaguar Health, Inc.?
The principal executive office address for Jaguar Health, Inc. is 200 Pine Street, Suite 400, San Francisco, California 94104.
What other items are reported in this 8-K filing besides the material agreement?
In addition to the material definitive agreement, the filing also reports on 'Unregistered Sales of Equity Securities' and 'Financial Statements and Exhibits'.
What was Jaguar Health, Inc.'s former company name?
Jaguar Health, Inc.'s former company name was Jaguar Animal Health, Inc., with a date of name change on August 30, 2013.
Filing Stats: 780 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2025-10-01 16:15:44
Key Financial Figures
- $0.0001 — ich registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Stock Mar
- $1.56 — . The purchase price of the Shares is $1.56 per share and the purchase price for th
- $1.56 m — se price for the Pre-Funded Warrants is $1.56 minus $0.0001. The Company intends to use
Filing Documents
- d20552d8k.htm (8-K) — 30KB
- d20552dex41.htm (EX-4.1) — 99KB
- d20552dex101.htm (EX-10.1) — 193KB
- 0001193125-25-226788.txt ( ) — 512KB
- jagx-20250928.xsd (EX-101.SCH) — 3KB
- jagx-20250928_lab.xml (EX-101.LAB) — 18KB
- jagx-20250928_pre.xml (EX-101.PRE) — 11KB
- d20552d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Pre-Funded Warrant, dated September 28, 2025, by and between Jaguar Health, Inc. and Brown Stone Capital Limited 10.1 Securities Purchase Agreement, dated September 28, 2025, by and between Jaguar Health, Inc. and Brown Stone Capital Limited 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. Date: October 1, 2025 By: /s/ Lisa A. Conte Lisa A. Conte Chief Executive Officer & President